cyrilzakka/clinical-trials huggingface dataset:
The Effect of Pilates and Myofascial Release on Flexibility

The aim of this study is to compare the short and long term effects of pilates and myofascial relaxation technique on flexibility, muscle strength, dynamic balance, neural tension and pain threshold. To evaluate the effects of myofascial release technique on neural tension. To evaluate the effects of pilates on neural tension. To evaluate the effects of the protocol applied in combination with pilates and myofascial release technique in healthy women.

Pilates is a synthesis of balance, breathing and movement systems that predict the unity of mind and body developed by Joseph Pilates. Breathing correctly and adequately allows more oxygen to go to all the tissues in our body. Pilates; It includes 6 key principles: breath, concentration, control, precision / accuracy, centering, rhythm / fluency. It activates every muscle in the body, gives balance and flexibility, and shapes the posture by improving the body. By correcting the posture, it protects the musculoskeletal system problems caused by the posture disorder and helps the body to be more flexible and increase the strength and endurance of the muscles. It provides control over all joint movements, especially the spine. It improves balance and coordination. Fascia is a single, inseparable connective tissue that wraps, supports, protects, connects all tissues. It is a dynamic structure with many sensory receptors, constantly changing and adaptable, it is the largest system in the human body. Myofascial release technique can be defined as low-intensity, long-term mechanical force applied to the myofascial complex in order to dissolve fascial adhesions, reduce pain, ensure optimal length of the muscle, and increase functionality. It has been shown that myofascial release applied to the hamstrings in healthy individuals provides an increase in the normal range of motion of the hip. The effects of Pilates and myofascial release technique on flexibility, muscle strength, dynamic balance, neural tension and pain threshold will be evaluated.

Eligibility Criteria:
Inclusion Criteria:

* Be between the ages of 18-50
* Be woman Having a score of 600 or more when the International Physical Activity Questionnaire (Short) was administered
* Not be in menopause
* Not having had lower extremity surgery
* No traumatic injury in the last 1 year

Exclusion Criteria:

* Women entering menopause
* International Physical Activity Questionnaire (Short) score less than 600
* Those who have had lower extremity surgery
* Those with traumatic injury in the last 1 year
Effects of Ulnar Styloid and Sigmoid Notch Fractures on Postoperative Wrist Function of Distal Radius Fracture Patients

To study the effects of ulnar styloid and sigmoid notch fractures on postoperative wrist function in patients with distal radius fracture

Patients treated for distal radius fracture in the Department of Orthopedic Trauma at the People's Hospital of Peking University will be selected for outpatient follow-up. Evaluation was based on Sartiento's modification of the Gartland and Werley score. Efficacy was assessed with wrist pain as the focus.The follow-up time is one year after the operation。

Eligibility Criteria:
Inclusion Criteria:

1. unilateral distal radius fracture with or without ulnar styloid fracture, closed fracture
2. distal radius fracture repaired by internal fixation using a palmar plate
3. age of ≥18 years
4. integral clinical data, a postoperative follow-up period of ≥12 months
5. distal radius fracture with normal union
6. provision of informed consent after receiving an explanation of the purpose of this study

Exclusion Criteria:

1. old fracture, pathological fracture, open fracture
2. bilateral distal radius fracture
3. fracture of other parts of the wrist (excluding the ulnar styloid)
Capsaicin 8% Patch for Spinal Cord Injury Neuropathic Pain

A prospective case control study to determine the effectiveness and longevity of 8% capsaicin patch(es) in treating neuropathic pain in persons with spinal cord injury. The investigators will study spinal cord injury patients at South Texas Veterans Health Care Systems Spinal Cord Injury inpatient unit and outpatient clinics.

The investigators will recruit \~ 20 patients with chronic spinal cord injury (SCI) and chronic neuropathic pain (\>6months) below level of injury who have failed multiple pharmacological agents. Pre-study data collection will include subjective description of pain, baseline visual analog scale (VAS), numeric pain rating scale (NPRS), a numerical scale such as short form (SF) 36 form that measures quality of life parameters, subjective functional independence (FIM) scores, and pain diagrams will be obtained on each participant. Written informed consent will be obtained. After randomization patients will be assigned to a different sequence of treatment.

All patients will receive either the treatment and control patches in a randomized order for a total of three treatment periods (control, treatment, treatment for example). When assigned to received treatment arm of study patients will receive Qutenza Capsaicin 8% patch(es) applied for 1 hour after pre- treatment with topical lidocaine. The control group will receive a low dose (0.04%) amount of capsaicin in patch form using an identical application procedure.

Investigators will give each patient a diary to self record daily VAS/NPRS scores. Investigators will then schedule routine f/u via telephone call at 2, 4, 8, and 12 weeks post application to accurately report onset of relief and obtain NPRS scores at 2, 4, 8, 12 week points. Patients will follow up in clinic at the end of the 12 week study to repeat data collection using our quality of life scale (SF 36) and FIM scores. Investigators will then use data analysis to record percentage of reduction in NPRS/ VAS, and changes in SF 36 and FIM scores at any given time point vs baseline. For those that continue to have pain relief at 12 week mark we will periodically call every 4 months after study completion to assess for total duration of pain relief for up to 1 year post application.

Eligibility Criteria:
Inclusion Criteria:

1. Diagnosis of SCI
2. Neuropathic pain below level of injury
3. Surface area of pain no larger than 2 patches
4. Failed or did not tolerate gabapentin 3600mg/day, pregabalin 600mg/day, capsaicin cream and/or lidocaine cream
5. Skin over painful area intact

Exclusion Criteria:

1. Pain over open wound
2. Previously documented allergy to capsaicin
3. Superficial burn over area of pain
4. Premorbid (before SCI) neuropathic pain
5. HIV/AIDS neuropathy
Stress Index to Individualize Mechanical Ventilation in ARDS

Acute respiratory distress syndrome (ARDS) is a widely prevalent and morbid disease for which the current standard treatment is supportive care and avoidance of complications with lung-protective ventilation. Lower-tidal volume ventilation has been largely accepted as a means of lung protective ventilation, but the mechanism for its effectiveness is not yet clear, and debate remains as to how best to choose positive end-expiratory pressure (PEEP). Reduction in driving pressure (plateau pressure minus PEEP) has been suggested as a possible means to minimize ventilator-induced lung injury. This protocol aims to identify the range of safe paired-settings of PEEP and tidal volume, with selection guided by driving pressure and the stress index, a tool to recognize potential lung hyperinflation during mechanical ventilation.


Eligibility Criteria:
Inclusion Criteria:

* Admitted to the Intensive Care Unit
* Receiving invasive mechanical ventilation via endotracheal or tracheostomy tube
* Presence of ARDS by Berlin Criteria (acute onset bilateral pulmonary infiltrates incompletely explained by left heart failure together with a PaO2/FiO2 of \<300 or SpO2/FiO2 \<315)

Exclusion Criteria:

* Inability to obtain surrogate consent
* Presence of specified comorbidities:

  1. pregnancy
  2. pre-existing severe chronic obstructive pulmonary disease, defined as FEV1 documented \< 1L or baseline hypercapnia
  3. cerebral edema
  4. known intra-cranial abnormality
  5. acute coronary syndrome
* Endotracheal or tracheostomy cuff leak
* Chest tube with persistent air leak
* Severe hemodynamic instability (defined as attending judgment that the patient is unable to safely tolerate ventilator manipulations)
* Presence of spontaneous respiratory activity as evidenced by examination of the ventilator waveform tracing
* Intrinsic PEEP of \> 5 cmH2O
* Assessment of study staff or patient's attending physician that the patient would not be a good study participant
Patient Care Management Strategies for Severe Heart Failure in Rhône-Alpes, France.

The heart failure is a chronic pathology with prevalence from 2 to 3% of general population, a death rate of 50% at 6 months for patients with stage IV, and a probability of death or hospitalization or emergency consultation of 40% at 3 years. The care of patients is heterogeneous, especially in light of the organization of therapeutic education offered to patients and patient monitoring modalities.

The aim of this study is to investigate the management strategies for patients with chronic heart failure stage III or IV NYHA, and heart failure patients with stage II NYHA with previous hospitalization for heart failure.

This is a longitudinal observational multicenter study comparing a management strategy including patient education and monitoring as part of a hospital dedicated organization and an organization of care as usually done in France.

The primary endpoint was a composite endpoint of morbidity and mortality involving deaths, unplanned readmissions and emergency visits for heart failure.

The expected number of patients is 720 patients (360 per strategy). The follow-up duration of 24 months.


Eligibility Criteria:
Inclusion Criteria:

* Chronic heart failure patient with left ventricular ejection fraction (LVEF) defined by an impaired LVEF less than or equal to 40%.
* Heart failure stage III or IV NYHA, or heart failure patients with stage II NYHA with previous hospitalization for heart failure.
* Patient who has received a written or oral information of the study
* Patient affiliated with French health Insurance

Exclusion Criteria:

* Patient refusal to participate in the study
* Progressive neoplastic pathology.
* Patient with impaired cognitive functions known.
* Patient subject to a measure of socio-legal protection.
* Heart failure secondary to curable causes (an arrhythmia, valvular dysfunction, myocardial infarction, bypass surgery scheduled, aortic stenosis, breaking rope...)
* Dyspnea pulmonary origin: pulmonary arterial hypertension pre-capillary origin catheterization, defined by a Pcap ≤15 mmHg.
* Patient who underwent ventricular mechanical assistance.
* Patient with acute breathlessness is explained by: a severe lung infection (CPT \<60% of predicted, ventricular ejection fraction \<60% predicted) or pulmonary embolism or respiratory failure with ambient air PaO2 (arterial oxygen pressure) below 60 mmHg or oxygen therapy.
* Dialysis patient
Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec 5.0 mg Chewable Tablet Medications (Study P04574)(COMPLETED)

This was a randomized, open-label, 2-way cross-over study, comparing desloratadine RediTab 2.5 mg to a marketed chewable antihistamine oral medication (Zyrtec® 5 mg

Chewable Tablet). Subject preference for one product or the other was determined. Acceptability of product attributes (Taste and Feeling in the Mouth) was rated using a "smile" face scale.


Eligibility Criteria:
Inclusion Criteria:

* Subject, and the parent/guardian of the subject, was to have demonstrated their willingness to participate in the study and comply with its procedures by signing a written Informed Consent.
* Subject was to be 6-11 years of age, of either sex and of any race.
* If female, subject was to be premenarcheal.
* Subject was to be willing to avoid eating, drinking, gum chewing, and teeth brushing for one hour prior to enrollment.
* Subject was to be free of any clinically significant disease that would interfere with study evaluations, including allergic rhinitis and respiratory infections.
* Subject was to have understood and been able to adhere to the dosing and visit schedules.

Exclusion Criteria:

* If female, subject who was pregnant, intended to become pregnant during the study or nursing.
* Subject had used any investigational product within 30 days prior to enrollment.
* Subject had any of the following clinical conditions: history of any significant medical conditions (based on reporting by parent or guardian): e.g., diabetes, heart disease, liver disease, kidney disease, breathing problems, cough with excessive phlegm, or persistent or chronic cough.
* Subject had a current medical condition that, in the opinion of the Investigator or designee, may interfere with the ability to discriminate taste (e.g., common cold, sinus infection, bronchial infection, allergic rhinitis, etc.).
* Subject was participating in any other clinical study(ies).
* Subject was part of the staff or a family member of the staff personnel directly involved with this study.
* Subject was allergic to or has sensitivity to the study drug or its excipients.
* Subject had a history of allergic reaction to prescription and/or OTC medications and/or food products.
* Subject had used any antihistamines within 24 hours prior to tasting as outlined in Section 9.4.7.
* Subject used sedatives, tranquilizers, or monoamine oxidase inhibitor drugs.
Sleep Apnea in Frail Elderly

Sleep apnea syndrome is common and increases with age. In the elderly, symptoms might be different than in the youngest people, and its consequences might be severe and atypical (falls, functional and cognitive decline).

Today, there is no specific tool to detect sleep apnea in the elderly. The goal of this study is to evaluate the accuracy of oximetry for detection of respiratory disturbances in sleep apnea in the hospitalized elderly.

Main goal: to define the more specific and sensitive cut-off of variability index of the oximetry to detect sleep apnea in the hospitalized elderly.

Secondary goals:

* sleep apnea prevalence in the elderly
* accuracy of other oximetry parameters (saturation line, oximetry desaturation index, autonomic arousals) for detection of respiratory disturbances in sleep apnea in the hospitalized elderly
* to determine the clinical and biological data associated with sleep apnea in the hospitalized elderly
* to determine the factors associated with the record failures and its prevalence
* to study the prevalence of the Periodic Limb Movements of Sleep in the hospitalized elderly

Study design: simultaneous records by oximetry and ventilatory polygraphy with tibial EMG in the hospitalized elderly in a geriatric readaptation unit.

Eligibility Criteria:
Inclusion Criteria:

* age \> 75 ans
* affiliation to the French health care system

Exclusion Criteria:

* hypoxemia with oxygenotherapy
* already known and treated sleep apnea syndrome
* mild to severe dementia (MMSE\<18/30)
* nocturnal neurpsychological disturbances
* acute organic failure
A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion

The primary purpose of this Phase 2 study is to optimize Plasmin delivery by comparing different delivery regimens in patients with peripheral arterial occlusion. The study includes a blinded plasminogen activator treatment group and a blinded plasminogen activator placebo group. The study will also assess safety and tolerability of Plasmin at 150 and 250 mg doses.


Eligibility Criteria:
Inclusion Criteria:

* Unilateral limb ischemia - Society of Vascular Surgery Categories I and IIa
* Onset of symptoms less than or equal to 14 days
* Thrombosed infrainguinal bypass graft or native artery
* Diagnosis by arteriography of occlusive thrombus in graft or artery
* Ability to embed the infusion catheter into the thrombus
* Women of childbearing potential must use contraception and have a negative pregnancy test

Exclusion Criteria:

* Any medical or social condition that may interfere with study participation
* Women who are pregnant or lactating
* Hemorrhagic stroke history
* Thrombotic or embolic stroke or cerebrovascular events (including transient ischemic attack) within one year
* Intracranial or spinal neurosurgery, or severe intracranial trauma in the last 3 months
* Major surgery, organ biopsy, or major trauma within the past 10 days
* Lumbar puncture or non-compressible arterial puncture in the past 10 days
* Intraocular surgery within the past 10 days
* Active gastrointestinal or organ bleeding
* Uncontrolled arterial hypertension (systolic blood pressure \>180 mmHg or diastolic blood pressure \>110 mmHg)
* Known intracranial neoplasm, aneurysm, or arteriovenous malformation
* Current bleeding diathesis
* Platelet count \<75 x 10e9/L
* Active graft infection
* Occlusion occurred within one month of synthetic graft placement
* Occlusion occurred within 6 months of autologous graft placement
* A sequential composite graft with dual outflows to correct multiple occlusions
* Medically unable to tolerate an open vascular procedure
* Known prothrombotic state
* Hemoglobin \<10.0 g/dL
* Impaired renal function or renal disease that constitutes a contraindication to contrast angiography, including creatinine \>2.0 mg/dL
* Treatment with a full dose plasminogen activator (PA) within the last 48 hours
* Treatment with a glycoprotein IIb/IIIa class of platelet inhibitor within the past 5 days
* Treatment with oral anticoagulants, and with an international normalized ratio of \>1.7
Modulation of Endothelial Dysfonction Using Vitamin C in Septic Shock Patients

Compare the microcirculatory reactivity before and after a 30-minute intravenous infusion of 40 mg/kg vitamin C and evaluate intra-individual variation of hemodynamic parameters between T0 and T1.

This is a transversal study allowing to compare the microcirculatory reactivity before and after a 30-minute intravenous infusion of 40 mg/kg vitamin C.

Design:

• A monocentric, open-label, transversal study

Sample size :

30 patients

Assessement:

Between 6 hours and 24 hours after admission, the patient will be included after collection of the non opposition.

There will be two evaluation times: T0 before the start of vitamin C's perfusion, and T1: 1 hour after the end.

No interim analysis is planned. Analysis will be performed at the end of the study after data review and freezing of data base.

Eligibility Criteria:
Inclusion Criteria:

* Age \> 18 years
* Septic shock patient, reanimated and stabilized defined as:

  * Patients with sepsis (suspected infection + 2 SOFA points) according to the latest international and the need to receive norepinephrine to maintain an average blood pressure above 65 mmHg
  * Patient supported for at least 6 hours, necessary for diagnostic management and hemodynamic optimization according to international standards and for less than 24 hours to limit confounding factors related to prolonged reanimation (sedation) and the empowerment of organ failures in general and vascular in particular. Hemodynamic stabilization will be defined as no increase in norepinephrine dosages

Exclusion Criteria:

* Pregnant or nursing women,
* Participation in another intervention research involving the human person or exclusion period following a previous research involving the human person
* Ward or curative patient
* Moribund patient
* Estimated life expectancy less than 1 month
Modifying Unconscious Tongue Movements in Adults With Developmental Stammer.

This is a pilot randomised controlled trial investigating whether using modification of saccadic eye movements can control lateral unconscious tongue positioning and enhance fluency in adults with a confirmed developmental stammer. This study is being conducted as part of an MSc by research qualification at the Institute of Technology Sligo in Ireland with a view to extending to PhD. The setting is home setting with all assessments either taking place at home via video link or in the institute. The study is being conducted in conjunction with the Community Speech and Language Therapist and has attained ethical approval through Sligo University Hospital (SUH) Ethics Committee.

Participants will be assessed for stammering severity either on line via video link or in the Institute of Technology Sligo Health Science \& Exercise Physiology Lab (B2004) at three time points: before intervention, after a five-week trial period and three months post completion. Participants will complete two assessments at each time to cater for "off" days. Participants will be required to practice quick eye movements at the start of words / syllables where dysfluencies are predicted for 10 minutes twice a day for the treatment period. Training in eye movement (saccade) modification will occur following the initial assessment in IT Sligo, or video link.

Participants will be assigned to one of two treatment arms. An experimental arm, and a control (placebo) arm. All participants will be assessed regarding their premonitory awareness of anticipated dysfluencies both before training and at the three month Based on advice from Community Speech and language Manager (Ms Sinead Carthy), participants will voice/video message the principle investigator once per week for this five-week period to confirm compliance.

Eligibility Criteria:
Inclusion Criteria:

* Adults age \> 18 years.
* A diagnosis of confirmed developmental stammer from SALT characterized by stammering on ≥ 3% of syllables.
* A proficiency in the English Language.
* No diagnosis of any emotional, behavioural, learning or neurological disorder.
* Cognitive ability to take part.
* Have previously completed a course of outpatient treatment for confirmed developmental stammer.

Exclusion Criteria:

* Younger than 18 years.
* Not having completed a traditional intervention for stammer.
* This research is not intended to replace current interventions but provide additional possibilities for those adults who have completed a standard programme of intervention and their developmental stammer still persists and a rate of ≥ 3% of syllables